8-KAcquisitions & DispositionsOther EventsExhibits & Filings

AbbVie Inc. 8-K Report, Acquisition Completed (May 26, 2015)

Filed May 26, 2015For Securities:ABBV

Summary

This 8-K filing from AbbVie Inc. on May 26, 2015, announces the successful completion of its acquisition of Pharmacyclics, Inc. following a tender offer. Approximately 87% of Pharmacyclics shares were tendered, paving the way for the subsequent merger. This acquisition represents a significant strategic move by AbbVie, aimed at bolstering its product pipeline and market position, particularly in the oncology and immunology sectors where Pharmacyclics had a notable presence with its drug Imbruvica. The filing details the terms of the acquisition, which allowed Pharmacyclics shareholders to elect between cash, AbbVie stock, or a combination thereof, based on a specified valuation and trading price of AbbVie's stock. The completion of this merger is a key event for AbbVie investors, signifying the integration of Pharmacyclics' assets and intellectual property into AbbVie's operations, with the expectation of future growth and synergies. Investors will be keen to monitor the financial performance and strategic integration of the acquired entity.

Key Highlights

  • 1AbbVie Inc. has successfully completed its acquisition of Pharmacyclics, Inc. through a tender offer and subsequent merger.
  • 2Approximately 87% of Pharmacyclics' outstanding shares were validly tendered and accepted for payment.
  • 3The acquisition was finalized on May 26, 2015, with Pharmacyclics becoming a wholly owned subsidiary of AbbVie.
  • 4Pharmacyclics shareholders had the option to receive mixed consideration (cash and stock), all-cash, or all-stock consideration for their tendered shares.
  • 5The transaction structure involved an initial tender offer followed by a two-step merger process, culminating in the absorption of Pharmacyclics.
  • 6AbbVie will file the required financial statements and pro forma information for Pharmacyclics in a future amendment to this report.
  • 7This filing confirms the consummation of a significant strategic acquisition for AbbVie, expected to enhance its therapeutic offerings.

Frequently Asked Questions

This 8-K filing announces the completion of AbbVie's acquisition of Pharmacyclics, Inc. It confirms that the tender offer has expired and the subsequent merger has been consummated, making Pharmacyclics a wholly owned subsidiary of AbbVie.

AbbVie acquired approximately 87% of Pharmacyclics' outstanding shares through the tender offer, which represented the majority needed to proceed with the merger.

Pharmacyclics shareholders who tendered their shares had the option to receive mixed consideration (a combination of cash and AbbVie stock), all-cash consideration, or all-stock consideration, subject to certain election and proration procedures outlined in the merger agreement.

AbbVie states in the filing that it intends to file the financial statements of Pharmacyclics and the required pro forma financial information as part of an amendment to this Current Report on Form 8-K, or otherwise, no later than 71 calendar days after the filing of this report.